Cargando…
A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2
Breast cancer is the most common type of female cancer. Reactive oxygen species (ROS) are vital in regulating signaling pathways that control cell survival and cell proliferation. Chemotherapeutic drugs such as anthracyclines induce cell death via ROS induction. Chemoresistance development is associ...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139508/ https://www.ncbi.nlm.nih.gov/pubmed/32110852 http://dx.doi.org/10.3390/cancers12030533 |
_version_ | 1783518781784457216 |
---|---|
author | Leung, Man-Hong Tsoi, Ho Gong, Chun Man, Ellen PS Zona, Stefania Yao, Shang Lam, Eric W.-F. Khoo, Ui-Soon |
author_facet | Leung, Man-Hong Tsoi, Ho Gong, Chun Man, Ellen PS Zona, Stefania Yao, Shang Lam, Eric W.-F. Khoo, Ui-Soon |
author_sort | Leung, Man-Hong |
collection | PubMed |
description | Breast cancer is the most common type of female cancer. Reactive oxygen species (ROS) are vital in regulating signaling pathways that control cell survival and cell proliferation. Chemotherapeutic drugs such as anthracyclines induce cell death via ROS induction. Chemoresistance development is associated with adaptive response to oxidative stress. NRF2 is the main regulator of cytoprotective response to oxidative stress. NRF2 can enhance cell growth, antioxidant expression, and chemoresistance by providing growth advantage for malignant cells. Previously, we identified BQ323636.1 (BQ), a novel splice variant of nuclear co-repressor NCOR2, which can robustly predict tamoxifen resistance in primary breast cancer. In this study, we found that BQ was overexpressed in epirubicin-resistant cells and demonstrated that BQ overexpression could reduce the levels of epirubicin-induced ROS and confer epirubicin resistance. In vivo analysis using tissue microarray of primary breast cancer showed direct correlation between BQ expression and chemoresistance. In vitro experiments showed BQ could modulate NRF2 transcriptional activity and upregulate antioxidants. Luciferase reporter assays showed that although NCOR2 repressed the transcriptional activity of NRF2, the presence of BQ reduced this repressive activity. Co-immunoprecipitation confirmed that NCOR2 could bind to NRF2 and that this interaction was compromised by BQ overexpression, leading to increased transcriptional activity in NRF2. Our findings suggest BQ can regulate the NRF2 signaling pathway via interference with NCOR2 suppressive activity and reveals a novel role for BQ as a modulator of chemoresistance in breast cancer. |
format | Online Article Text |
id | pubmed-7139508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71395082020-04-10 A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2 Leung, Man-Hong Tsoi, Ho Gong, Chun Man, Ellen PS Zona, Stefania Yao, Shang Lam, Eric W.-F. Khoo, Ui-Soon Cancers (Basel) Article Breast cancer is the most common type of female cancer. Reactive oxygen species (ROS) are vital in regulating signaling pathways that control cell survival and cell proliferation. Chemotherapeutic drugs such as anthracyclines induce cell death via ROS induction. Chemoresistance development is associated with adaptive response to oxidative stress. NRF2 is the main regulator of cytoprotective response to oxidative stress. NRF2 can enhance cell growth, antioxidant expression, and chemoresistance by providing growth advantage for malignant cells. Previously, we identified BQ323636.1 (BQ), a novel splice variant of nuclear co-repressor NCOR2, which can robustly predict tamoxifen resistance in primary breast cancer. In this study, we found that BQ was overexpressed in epirubicin-resistant cells and demonstrated that BQ overexpression could reduce the levels of epirubicin-induced ROS and confer epirubicin resistance. In vivo analysis using tissue microarray of primary breast cancer showed direct correlation between BQ expression and chemoresistance. In vitro experiments showed BQ could modulate NRF2 transcriptional activity and upregulate antioxidants. Luciferase reporter assays showed that although NCOR2 repressed the transcriptional activity of NRF2, the presence of BQ reduced this repressive activity. Co-immunoprecipitation confirmed that NCOR2 could bind to NRF2 and that this interaction was compromised by BQ overexpression, leading to increased transcriptional activity in NRF2. Our findings suggest BQ can regulate the NRF2 signaling pathway via interference with NCOR2 suppressive activity and reveals a novel role for BQ as a modulator of chemoresistance in breast cancer. MDPI 2020-02-26 /pmc/articles/PMC7139508/ /pubmed/32110852 http://dx.doi.org/10.3390/cancers12030533 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Leung, Man-Hong Tsoi, Ho Gong, Chun Man, Ellen PS Zona, Stefania Yao, Shang Lam, Eric W.-F. Khoo, Ui-Soon A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2 |
title | A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2 |
title_full | A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2 |
title_fullStr | A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2 |
title_full_unstemmed | A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2 |
title_short | A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2 |
title_sort | splice variant of ncor2, bq323636.1, confers chemoresistance in breast cancer by altering the activity of nrf2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139508/ https://www.ncbi.nlm.nih.gov/pubmed/32110852 http://dx.doi.org/10.3390/cancers12030533 |
work_keys_str_mv | AT leungmanhong asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT tsoiho asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT gongchun asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT manellenps asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT zonastefania asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT yaoshang asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT lamericwf asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT khoouisoon asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT leungmanhong splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT tsoiho splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT gongchun splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT manellenps splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT zonastefania splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT yaoshang splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT lamericwf splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 AT khoouisoon splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2 |